西格列汀联合阿卡波糖治疗2型糖尿病患者的临床效果研究

The Clinical Effect of Cigliptin Combined with Acarbose in the Treatment of Type 2 Diabetes Mellitus

目的探讨西格列汀联合阿卡波糖治疗2型糖尿病患者的临床应用效果。方法选取太原北方医院2017年9月至2018年9月收治的2型糖尿病患者230例为研究对象,平均分为对照组和实验组,各115例。对照组进行常规饮食、合理运动、保持生活规律以及心理常规护理,并口服与阿卡波糖片;实验组在对照组的基础上进行口服磷酸西格列汀片。观察每组患者的临床疗效、血糖指标、氧化应激水平以及胰岛素相关指标。结果实验组的总有效率90.43%高于对照组73.04%,差异有统计学意义(P<0.05)。治疗后,实验组GLUT4、胰岛β细胞功能指数、超氧化物歧化酶水平分别为(5.93±0.45)mmol/L,(63.97±14.90)%,(188.33±20.72)kU/L,对照组分别为(3.74±0.21)mmol/L、(48.44±14.78)%、(147.15±21.22)kU/L,差异均有统计学意义(P<0.05)。治疗后,实验组空腹胰岛素、胰岛素抵抗指数、丙二醛、空腹血糖、餐后2 h血糖(2 h PG)和平均血糖波动幅度水平分别为(78.78±18.02)mU/L、(5.29±0.99)%、(2.04±0.74)μmol/L、(7.13±0.98)mmol/L、(8.54±1.40)mol/L、(3.18±0.43)mmol/L;对照组分别为(95.33±15.14)mU/L、(7.30±1.31)%、(3.17±0.83)μol/L、(9.79±1.04)mmol/L、(11.51±1.61)mol/L、(5.41±0.62)mmol/L,差异均有统计学意义(P<0.05)。实验组和对照组的药物不良反应发生率分别为11.30%、13.91%,差异无统计学意义(P>0.05)。结论2型糖尿病患者服用西格列汀片联合阿卡波糖可以控制血糖水平,降低血糖波动,改善机体GLUT-4水平,降低患者氧化应激反应。

Objective To explore the clinical effect of cigliptin combined with acarbose in the treatment of type 2 diabetes.Methods A total of 230 patients with type 2 diabetes admitted to Taiyuan North Hospital from September 2017 to September 2018 were selected as study subjects,and divided into control group and experimental group on average,with 115 cases each.The control group received regular diet,reasonable exercise,regular life and psychological nursing,and oral administration of acarbose tablets;On the basis of the control group,the experimental group received oral siglitine phosphate tablets.The clinical efficacy,blood glucose index,oxidative stress level and insulin-related indexes of each group were observed.Results The total effective rate of the experimental group was 90.43%higher than that of the control group(73.04%),the difference was statistically significant(P<0.05).After treatment,GLUT4,islet cell function index and superoxide dismutase levels were(5.93±0.45)mmol/L,(63.97±14.90)%and(188.33±20.72)kU/L in the experimental group and(3.74±0.21)mmol/L,(48.44±14.78)%and(147.15±21.22)kU/L in the control group,respectively,with statistically significant differences(P<0.05).After treatment,the levels of fasting insulin,insulin resistance index,malondialdehyde,fasting glucose,postprantional 2-h blood glucose(2 h PG)and mean glucose fluctuation amplitude were(78.78±18.02)mU/L,(5.29±0.99)%,(2.04±0.74)mol/L,(7.13±0.98)mmol/L,(8.54±1.40)mol/L,(3.18±0.43)mmol/L,respectively.The control group was(95.33±15.14)mU/L,(7.30±1.31)%,(3.17±0.83)ol/L,(9.79±1.04)mmol/L,(11.51±1.61)mol/L,(5.41±0.62)mmol/L,respectively,with statistically significant differences(P<0.05).The incidence of adverse drug reactions in the experimental group and the control group was 11.30%and 13.91%,respectively,with no statistically significant difference(P>0.05).Conclusion Patients with type 2 diabetes can control their blood glucose level by taking cigliptin and acarbose,Reduce blood sugar fluctuations,Improve GLUT-4 level,Reduce the oxidative stress of patients.